You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR ATEZOLIZUMAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for atezolizumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00781612 ↗ A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies Recruiting Hoffmann-La Roche Phase 2 2008-10-16 This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
NCT00781612 ↗ A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies Recruiting Genentech, Inc. Phase 2 2008-10-16 This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
NCT01375842 ↗ A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors Completed Genentech, Inc. Phase 1 2011-06-21 This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for atezolizumab

Condition Name

Condition Name for atezolizumab
Intervention Trials
Non-Small Cell Lung Cancer 44
Hepatocellular Carcinoma 41
Breast Cancer 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for atezolizumab
Intervention Trials
Carcinoma 151
Lung Neoplasms 116
Carcinoma, Non-Small-Cell Lung 110
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for atezolizumab

Trials by Country

Trials by Country for atezolizumab
Location Trials
Italy 547
Spain 502
China 87
Ukraine 81
Belgium 78
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for atezolizumab
Location Trials
California 187
New York 166
Texas 154
Tennessee 135
Florida 131
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for atezolizumab

Clinical Trial Phase

Clinical Trial Phase for atezolizumab
Clinical Trial Phase Trials
Phase 4 7
Phase 3 88
Phase 2/Phase 3 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for atezolizumab
Clinical Trial Phase Trials
Recruiting 286
Not yet recruiting 133
Active, not recruiting 108
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for atezolizumab

Sponsor Name

Sponsor Name for atezolizumab
Sponsor Trials
Hoffmann-La Roche 183
Genentech, Inc. 116
National Cancer Institute (NCI) 75
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for atezolizumab
Sponsor Trials
Other 639
Industry 522
NIH 75
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.